Cambridge duo in latest Red Herring innovation wave
Cambridge Cancer Genomics and Ieso Digital Health have been named by Red Herring as key innovators in its 2020 Top 100 Europe winners.
Each business is playing a vital role in elevating the standards of healthcare in the UK and globally – Ieso in mental health and CCG in personalised medicines for cancer patients.
Ieso is this publication’s reigning Business of the Year and its technology is especially pertinent during the COVID-19 lockdown which is putting an even greater strain on people with mental illness.
Ieso has become a leader in online cognitive behavioural therapy provision and an innovator in mental healthcare.
Alex Vieux, publisher and CEO of Red Herring, said: “We had the toughest time in years because so many entrepreneurs had crossed significant milestones so early in the European tech ecosystem.
“We believe Ieso embodies the vision, drive and innovation that define a successful entrepreneurial venture. Ieso should be proud of its accomplishment, as the competition was very strong.”
As a clinically proven digital healthcare provider, Ieso’s vision is to deliver and develop services that remove barriers to evidence-based mental health treatment and recovery.
Today, Ieso partners with 75 NHS clinical commissioning groups across England under the IAPT programme (Improving Access to Psychological Therapies), providing online cognitive behavioural therapy that enables clinicians to treat patients remotely within a secure, text-based and confidential environment.
Ieso has treated more than 50,000 patients and conducted over 250,000 hours of therapy with its service to date.
As part of its development arm, last year Ieso launched its Eight Billion Minds programme that applies deep learning to real-world data from therapy sessions to understand more about what works for whom and develop digital tools to support and deliver therapy at scale.
CCG.ai exists to ensure that each patient has the right drug, at the right time, to beat their cancer The business builds the software to enable data-driven precision oncology and systematically develop data-driven biomarkers indicative of treatment response.
Led by CEO John Cassidy, CCG believes that increasing amounts of clinical and genomic data have the potential to transform cancer treatment and enable oncologists to make smarter decisions about which drug to use in which circumstance.